Skip to main content
Signal8
Launch Terminal

NYMOX PHARMACEUTICAL CORP (NYMXF)

Nymox Pharmaceutical Corporation is a biopharmaceutical firm focused on the research and development of medications for the aging population. Operating internationally, including in Canada, the United States, and Europe, the company's flagship drug candidate is Fexapotide Triflutate (NX-1207). This compound is currently undergoing various clinical trials for conditions such as benign prostatic hyperplasia and low-grade localized prostate cancer, with preclinical investigations also underway for hepatocellular carcinoma. Beyond its drug pipeline, Nymox develops and offers two diagnostic products: NicAlert, which identifies tobacco usage, and TobacAlert, designed to detect exposure to secondhand smoke. The company is also actively engaged in developing treatments for Alzheimer's disease. Nymox Pharmaceutical Corporation was established in 1989 and maintains its headquarters in Nassau, the Bahamas.

Sector: In Vitro & In Vivo Diagnostic Substances

Industry: Biotechnology

Nymox Pharmaceutical Corporation logo

Nymox Pharmaceutical Corporation

OTC:NYMXFHealthcare
+96.33%$0.0589
Mkt Cap-
Float56.1M
O/S-
Vol
$ Vol
RVOL
Inst Own-
Earnings
Dilution
Nymox Pharmaceutical Corporation logoOTC:NYMXF$0.0589+96.33%
Phase Distribution
6 lead-sponsored trials·0 active·6 completed
Phase 22
Phase 34
Status Overview
Completed6

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Phase
  • Phase 3
    Completed

    Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)

    NX-1207, Placebo

    Benign Prostatic Hyperplasia

    Enrollment
    500
    Start
    Apr 2009
    Primary Completion
    Nov 2013
    Completion
    Nov 2013
    NCT00918983
  • Phase 3
    Completed

    Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018

    NX-1207, Placebo

    Benign Prostatic Hyperplasia (BPH)

    Enrollment
    500
    Start
    May 2009
    Primary Completion
    May 2014
    Completion
    May 2014
    NCT00945490
  • Phase 3
    Completed

    Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)

    NX-1207

    Benign Prostatic Hyperplasia

    Enrollment
    192
    Start
    Sep 2011
    Primary Completion
    Jan 2013
    Completion
    Jan 2013
    NCT01438775
  • Phase 3
    Completed

    Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)

    NX-1207

    Benign Prostatic Hyperplasia, BPH +2

    Enrollment
    160
    Start
    Apr 2013
    Primary Completion
    Oct 2014
    Completion
    Oct 2014
    NCT01846793
  • Phase 2
    Completed

    Phase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate)

    2.5 mg NX-1207, 0.125 mg NX-1207

    Benign Prostatic Hyperplasia (BPH), Enlarged Prostate

    Enrollment
    85
    Start
    May 2007
    Primary Completion
    Jan 2008
    Completion
    May 2008
    NCT00759135
  • Phase 2
    Completed

    Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

    NX-1207 2.5 mg, NX-1207 15 mg

    Prostate Cancer

    Enrollment
    141
    Start
    Feb 2012
    Primary Completion
    Oct 2015
    Completion
    Oct 2015
    NCT01620515
Search ClinicalTrials.gov for “Nymox Pharmaceutical”